1 not yet recruiting, 1 recruiting, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow DynamiCure Biotechnology: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer DCSZ11, Radiation, Capecitabine - Rectal Cancer | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 30 | 2026-11-01 | 2026-10-28 |
| DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors DCSZ11, Pembrolizumab, Doxorubicin - Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | DynamiCure Biotechnology | 320 | 2023-06-28 | 2025-06-26 |
| DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors DCBY02 - Advanced or Metastatic Solid Tumors | Phase 1 | Terminated | DynamiCure Biotechnology | 5 | 2022-10-26 | 2024-03-06 |
Rectal Neoplasms (1)
Capecitabine (1) · Doxorubicin (1) · Oxaliplatin (1) · Radiation (1) · pembrolizumab (1) · tebentafusp (1)
United States (3) · Australia (1) · South Korea (1) · Taiwan (1)